Biocept is offering 6.25 million shares of its common stock and warrants to purchase up to 6.25 million shares of the common stock at a combined price $1.20 per share and warrant.
Both Opko and Phillip Frost will pay penalties and refrain from certain activities. Frost had been accused by the SEC of participating in market manipulation schemes.
The company was hit with an SEC lawsuit last week and said it expects the Nasdaq matter to be "resolved favorably" but it cannot estimate when trading will resume.
In its response, the company accused the Securities and Exchange Commission's lawsuit of containing "serious factual inaccuracies."
The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.
Qiagen terminated the first project for an NGS-based clinical trial assay after its pharmaceutical partner's phase II drug trial failed to meet its endpoint.
Company Founder and CEO Elizabeth Holmes has agreed to pay a $500,000 penalty. She is also barred from serving as an officer or director of a publicly traded company for 10 years.
The company issued more than 1.8 million shares of its common stock to several of its trade creditors to erase debt that it owed them, Precipio said in an SEC document.
The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order.